What BioMed Technology Holdings does

BioMed Technology Holdings Limited is a Hong Kong-based microbiome biotech company founded in September 2018 by professors and alumni of the Chinese University of Hong Kong (CUHK) and incubated at the Hong Kong Science Park. The company operates a vertically integrated platform that combines gut microbiome DNA testing — using real-time fluorescent qPCR panels (HK$1,200–HK$3,200) and third-generation 16S rRNA long-read sequencing (HK$3,800) — with personalized probiotic supplementation under its PGut brand. Its proprietary E3 triple-element formula combines probiotic strains (including the patented Lactobacillus plantarum GKM3), triple prebiotics, and the HK-LP postbiotic, protected by MAOC-LAB microencapsulation technology that claims 95% gastric acid resistance and 98% survival in simulated digestive conditions.

The company serves health-conscious consumers across Hong Kong, Macau, Mainland China, and Thailand through a hybrid D2C model: its own e-commerce storefront (shop.biomed.hk), three branded clinic/retail locations in Causeway Bay, Chai Wan, and Tsim Sha Tsui, third-party pharmacy and retail chains (Mannings, Pricerite), and SF Express fulfillment. Sub-brands extend the platform into probiotic skincare (PSkIn EC Cream) and pet health (PawsBiome DNA test and Pawbiotics supplements). The go-to-market blends product-led growth (tests as lead generators for supplement subscriptions) with community-led and content-marketing motions anchored by CUHK academic credibility and expert content.

BioMed monetizes through one-time test fees and repeat supplement purchases (HK$220–HK$440 per pack), with reported institutional backing from a USD 2 million oversubscribed seed round in April 2023 (Alibaba Hong Kong Entrepreneurs Fund, Gobi Partners GBA, TIMC) followed by an April 2024 investment from CUHK Innovation Limited. The company holds multiple registered patents and operates with an 11–50 person team.

Name

BioMed Technology Holdings

Legal name

BioMed Technology Holdings Limited

Website

https://biomed.hk

Company type

Private

Founded year

2018

Operating status

Operating

Headcount range

11–50 employees

Short description

BioMed Technology Holdings is a Hong Kong microbiome biotech company that combines gut DNA testing (qPCR and 16S rRNA) with personalized probiotic supplements under its PGut, PSkIn, and PawsBiome brands, serving health-conscious consumers in Hong Kong, Macau, Mainland China, and Thailand through D2C, retail clinics, and pharmacy chains.

Ownership category

akta.pro rank

Product category

Probiotic Supplements

NAICS

Medical and Diagnostic Laboratories (62151), Medical Laboratories (621511), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Services-Medical Laboratories (8071), Services-Commercial Physical & Biological Research (8731), Services-Testing Laboratories (8734)

akta.pro primary industry

Microbiome Diagnostics & Biomarker Platforms (gut/skin/oral/vaginal) (HLAAAFAH)

akta.pro secondary industries

Probiotics & Digestive Health Supplements (CRADAGAF), Microbiome Analytics, Sequencing & Bioinformatics Platforms (HLAAAFAI), Probiotics (Strains, Spore-Formers, Synbiotic Components) (AFAJAKAE), Molecular Diagnostics & Genomics Laboratories (HLAFAMAE)

Keywords

• Microbiome DNA testing
• Probiotic supplements
• Personalized gut health
• Pet microbiome products
• Probiotic skincare

Headquarters

HQ city

Causeway Bay

HQ country

Hong Kong SAR China

HQ region

Asia

Offices4 records

Markets served

GTM type

B2C

Offering type

Hardware or Manufacturing

Cost components

Supply Chain

Revenue model

1. Gut Microbiome DNA Testing Services: One-time testing services including qPCR DNA panels (HK$1,200–HK$3,200) and 16S rRNA TGS sequencing (HK$3,800). Tests are purchased individually and include professional consultation and report interpretation.
2. PGut Probiotic Supplements: Recurring sales of proprietary probiotic supplement products across multiple lines (PGut E3, Vitabac, Immune, Kids, Mood, SupremeSlim, Allergy series). Supplements range from HK$220–HK$440 per unit and are sold via e-commerce, retail, and own-brand stores. Post-test recommendations drive repeat purchases.
3. Pet Healthcare Products: Sales of PawsBiome pet gut DNA tests and Pawbiotics customized pet probiotic supplements (HK$380–HK$900), targeting the expanding pet health market in Asia.

Pricing tiers

Go-to-market motion3 records

Distribution channels5 records

Marketing channels7 records

Core offering

BioMed Technology Holdings is a Hong Kong microbiome biotech company that provides gut microbiome DNA testing services (qPCR panels and 16S rRNA TGS sequencing) and a proprietary line of personalized probiotic supplements under the PGut brand using an E3 triple-element formula. The vertically integrated platform links consumer microbiome test results to tailored probiotic, prebiotic, and postbiotic (HK-LP) product recommendations spanning human gut health, probiotic skincare (PSkIn), and pet healthcare (PawsBiome and Pawbiotics).

Product overview

BioMed Technology Holdings is a Hong Kong microbiome biotech company founded by CUHK professors and alumni, operating from Hong Kong Science Park. The company offers a comprehensive health platform centered on gut microbiome testing and personalized probiotic supplementation. The core product lines include the PGut E3 probiotic series (available in Premium, SupremeSlim, Allergy, Mood+, Kids, and VitaBac variants) combining patented probiotic strains with triple prebiotics and postbiotics (HK-LP), PSkIn probiotic skincare products, and pet health solutions (PawsBiome/Pawbiotics). Testing services comprise qPCR DNA testing panels (Platinum, Allergy, Obesity, GI Toxin, Core Microbiota, Baby First 1000-day, and Resilience & Immunity) and 16S rRNA next-generation sequencing (TGS). The company integrates microbiome data analysis with big data to develop personalized health solutions spanning human gut health, skin health, and pet healthcare.

Differentiator

Problem solved

Functional benefit

Brands

• PGut: Primary probiotic supplement brand offering gut health products including E3 series probiotics, immune probiotics, vitabac probiotics, and children's probiotics. Products include PGut Premium E3, PGut SupremeSlim E3, PGut Allergy E3, PGut Mood+ E3, and PGut Kids Allergy Relieve Probiotics.
• PSkIn
• PawsBiome
• Pawbiotics

Products and services

• PGut Premium Probiotics E3

Quantifiable outcome

• Probiotic strains demonstrate 95% resistance to gastric acid, ensuring viability through the digestive system.
• +4 more outcomes

Segments5 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Partnerships

Seven partnerships are on record, tiered core and supporting.

• Hong Kong Science ParkcoreStrategic or Co-development PartnerBioMed is nurtured by Hong Kong Science Park, which provides R&D infrastructure, laboratory facilities, incubation support, and access to the broader biotech ecosystem in Hong Kong.
• Chinese University of Hong Kong (CUHK)coreStrategic or Co-development PartnerBioMed was founded by CUHK professors and alumni. The company maintains deep academic ties with CUHK's School of Biomedical Sciences, Department of Orthopaedics and Traumatology, and School of Chinese Medicine. Key advisors include Professor Stephen Tsui (bioinformatics) and Professor Lin Zhixiu (Chinese medicine).
• Mannings (Convenience/Pharmacy Chain)supportingChannel Partner/ Reseller/ DistributorPGut probiotic products are available for purchase at Mannings pharmacy stores across Hong Kong and through Mannings' online platform.
• Pricerite (Retail Chain)supportingChannel Partner/ Reseller/ DistributorPGut probiotic products are distributed through Pricerite retail stores across multiple locations in Hong Kong including Causeway Bay, Tsim Sha Tsui, North Point, Mong Kok, Kowloon Bay, Kwai Fong, Tseung Kwan O, Ma On Shan, and Sha Tin.
• Hong Kong Institute of Molecular (HKIM)supportingStrategic or Co-development PartnerAcademic research partner listed on BioMed's website as a cooperation partner for gut microbiome research.
• University of Hong Kong (HKU)supportingStrategic or Co-development PartnerAcademic research partner listed on BioMed's website as a cooperation partner in the Hong Kong Society of Gut Microbiome.
• Hong Kong Society of Gut MicrobiomesupportingStrategic or Co-development PartnerProfessional society co-founded by BioMed's CTO Dr. Zhou Junwai Wayne as Chief Secretary. Society supports research collaboration and knowledge exchange in gut microbiome science.

Scale indicators4 records

Recent moves6 records

Expansion highlights6 records

Broad incumbents

• BioGaia: Sweden-listed global probiotic brand with clinically documented Lactobacillus reuteri strains across gut, immune, and oral health categories. A broad incumbent shaping the consumer probiotics category in which BioMed competes with its PGut line.
• Yakult Honsha: Japan-based global probiotic dairy and supplement giant with massive Asian retail penetration. A broad incumbent that defines consumer expectations (and pricing) for probiotic products across Hong Kong and Greater China, the markets BioMed targets.

Direct peers

• Viome Life Sciences: US-based microbiome testing company selling gut microbiome sequencing combined with personalized nutrition and supplements. Operates the same test-to-product model as BioMed, with retail and DTC distribution, and is the canonical direct peer for a personalized gut-health platform.
• DayTwo: Israel/US microbiome company combining gut microbiome analysis with personalized nutrition recommendations and (historically) microbiome-targeted supplements. Closely mirrors BioMed's qPCR-style test plus personalised product loop targeting metabolic health.
• ZOE: UK consumer health company that pairs at-home gut microbiome testing with personalized dietary recommendations and a subscription program. Comparable as a science-backed, content-led DTC microbiome brand targeting mainstream health-conscious consumers.
• Sun Genomics (formerly Thryve): US microbiome testing and custom-formulated probiotic company. The closest pure-play direct peer — gut DNA test that drives bespoke multi-strain probiotic blends, identical functional loop to BioMed's PGut system.
• Atlas Biomed: UK/EU-based consumer genetic and gut microbiome testing company offering personalised health and nutrition recommendations, comparable to BioMed's combination of qPCR/16S rRNA testing with follow-on product recommendations.
• GenieBiome: Singapore precision gut microbiome company (spun out of NUS Medicine) offering gut microbiome testing and microbiome-targeted interventions for metabolic and gut health. Asia-region direct peer with overlapping DNA-based diagnostics and consumer health positioning.
• AMILI: Singapore-based microbiome analytics and consumer testing company with Southeast Asia reach. Comparable to BioMed as an Asian microbiome test-and-recommend platform targeting consumer gut and metabolic health.

Emerging players

• Carbiotix: Sweden-based microbiome testing and prebiotic/probiotic formulation provider focused on gut health APIs and B2B partnerships. Comparable on the metagenomics-services technology side to BioMed's 16S rRNA platform, but operating at an earlier commercial stage.

Market position

Strengths5 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• YouTubeyoutube.com/channel/UCGGrHM9x5hsrPTLYCttPQoA
• Facebookfacebook.com/PGUT.HK
• Instagraminstagram.com/pgut_hk
• LinkedInlinkedin.com/company/biomed-technology-holdings-limited

Compliance10 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Funding overview

Funding rounds3 records

Investors5 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about BioMed Technology Holdings